|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Estrogen upregulates DNA2 expression through the PI3K-AKT pathway in endometrial carcinoma显示文摘Endometrial cancer is the most common gynecological malignancy,affecting up to 3%of women at some point during their lifetime(Morice et al.,2016;Li and Wang,2021).Based on the pathogenesis and bio‑logical behavioral characteristics,endometrial cancer can be divided into estrogen-dependent(I)and non-estrogen-dependent(II)types(Ulrich,2011).Type I accounts for approximately 80%of cases,of which the majority are endometrioid carcinomas,and the remaining are mucinous adenocarcinomas(Setiawan et al.,2013). | Xinyan WANG Xiuling XU Ting ZHANG Yang JIN Sheng XU Lifeng CHEN Yucheng LAI Ling ZHANG Ruolang PAN Yan YU | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，3： | 2 |
| 2 | Targeting TRMT5 suppresses hepatocellular carcinoma progression via inhibiting the HIF-1αpathways显示文摘Accumulating evidence has confirmed the links between transfer RNA(tRNA)modifications and tumor progression.The present study is the first to explore the role of tRNA methyltransferase 5(TRMT5),which catalyzes the m1G37 modification of mitochondrial tRNAs in hepatocellular carcinoma(HCC)progression.Here,based on bioinformatics and clinical analyses,we identified that TRMT5 expression was upregulated in HCC,which correlated with poor prognosis.Silencing TRMT5 attenuated HCC proliferation and metastasis both in vivo and in vitro,which may be partially explained by declined extracellular acidification rate(ECAR)and oxygen consumption rate(OCR).Mechanistically,we discovered that knockdown of TRMT5 inactivated the hypoxia-inducible factor-1(HIF-1)signaling pathway by preventing HIF-1αstability through the enhancement of cellular oxygen content.Moreover,our data indicated that inhibition of TRMT5 sensitized HCC to doxorubicin by adjusting HIF-1α.In conclusion,our study revealed that targeting TRMT5 could inhibit HCC progression and increase the susceptibility of tumor cells to chemotherapy drugs.Thus,TRMT5 might be a carcinogenesis candidate gene that could serve as a potential target for HCC therapy. | Qiong ZHAO Luwen ZHANG Qiufen HE Hui CHANG Zhiqiang WANG Hongcui CAO Ying ZHOU Ruolang PAN Ye CHEN | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，1： | 1 |
| 3 | A novel Trmt5-deficient zebrafish model with spontaneous inflammatory bowel disease-like phenotype显示文摘Dear Editor,Inflammatory bowel disease(IBD),a complex syndrome characterized by chronic inflammation of the gastrointestinal tract,is considered a global health problem,especially prevalent in western developed countries and with accelerating incidence in the developing world over the last decade.1 To date,the primary etiology of IBD remains elusive. | Qiong Zhao Hui Chang Jing Zheng Ping Li Lidan Ye Ruolang Pan Di Li Jian-Zhong Shao Robert Chunhua Zhao Ye Chen | 2023 | Signal Transduction and Targeted Therapy2023，8，3： | 1 |
| 4 | Luteolin suppresses oral carcinoma 3(OC3) cell growth and migration via modulating polo-like kinase 1(PLK1) expression and cellular energy metabolism显示文摘Oral squamous cell carcinoma(OSCC)is a prevalent malignant tumor affecting the head and neck region(Leemans et al.,2018).It is often diagnosed at a later stage,leading to a poor prognosis(Muzaffar et al.,2021;Li et al.,2023).Despite advances in OSCC treatment,the overall 5-year survival rate of OSCC patients remains alarmingly low,falling below 50%(Jehn et al.,2019;Johnson et al.,2020).According to statistics,only 50%of patients with oral cancer can be treated with surgery.Once discovered,it is more frequently at an advanced stage.In addition,owing to the aggressively invasive and metastatic characteristics of OSCC,most patients die within one year of diagnosis.Hence,the pursuit of novel therapeutic drugs and treatments to improve the response of oral cancer to medication,along with a deeper understanding of their effects. | Pengfei GAO Wentao ZHANG Yujie LIN Ruijie LU Zijian LOU Gang LU Ruolang PAN Yunfang CHEN | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员